Assessment of the efficacy and safety of intravenous conivaptan in euvolemic and hypervolemic hyponatremia
- PMID: 17664863
- DOI: 10.1159/000106456
Assessment of the efficacy and safety of intravenous conivaptan in euvolemic and hypervolemic hyponatremia
Abstract
Background: Most cases of hyponatremia--serum sodium concentration ([Na+]) < 135 mEq/l (< 135 mM)--are associated with an elevated plasma arginine vasopressin level. This study investigated the efficacy and tolerability of intravenous conivaptan (YM087), a vasopressin V1A/V2-receptor antagonist, in treating euvolemic and hypervolemic hyponatremia.
Methods: Eighty-four hospitalized patients with euvolemic or hypervolemic hyponatremia (serum [Na+] 115 to < 130 mEq/l) were randomly assigned to receive intravenous placebo or conivaptan administered as a 30-min, 20-mg loading dose followed by a 96-hour infusion of either 40 or 80 mg/day. The primary efficacy measure was change in serum [Na+], measured by the baseline-adjusted area under the [Na+]-time curve. The secondary measures included time from first dose to a confirmed > or = 4 mEq/l serum [Na+] increase, total time patients had serum [Na+] > or = 4 mEq/l higher than baseline, change in serum [Na+] from baseline to the end of treatment, and number of patients with a confirmed > or = 6 mEq/l increase in serum [Na+] or normal [Na+] (> or = 135 mEq/l).
Results: Both conivaptan doses increased area under the [Na+]-time curve during the 4-day treatment (p < 0.0001 vs. placebo). From baseline to the end of treatment, the least-squares mean +/- standard error serum [Na+] increase associated with placebo was 0.8 +/- 0.8 mEq/l; with conivaptan 40 mg/day, 6.3 +/- 0.7 mEq/l; and with conivaptan 80 mg/day, 9.4 +/- 0.8 mEq/l. Conivaptan significantly improved all secondary efficacy measures (p < 0.001 vs. placebo, both doses). Conivaptan was generally well tolerated, although infusion-site reactions led to the withdrawal of 1 (3%) and 4 (15%) of patients given conivaptan 40 and 80 mg/day, respectively.
Conclusion: Among patients with euvolemic or hypervolemic hyponatremia, 4-day intravenous infusion of conivaptan 40 mg/day significantly increased serum [Na+] and was well tolerated.
2007 S. Karger AG, Basel
Similar articles
-
Assessment of the efficacy and safety of intravenous conivaptan in patients with euvolaemic hyponatraemia: subgroup analysis of a randomized, controlled study.Clin Endocrinol (Oxf). 2008 Jul;69(1):159-68. doi: 10.1111/j.1365-2265.2007.03149.x. Epub 2008 Jul 1. Clin Endocrinol (Oxf). 2008. PMID: 18034777 Clinical Trial.
-
Pharmacokinetics of conivaptan hydrochloride, a vasopressin V(1A)/V(2)-receptor antagonist, in patients with euvolemic or hypervolemic hyponatremia and with or without congestive heart failure from a prospective, 4-day open-label study.Clin Ther. 2009 Jul;31(7):1542-50. doi: 10.1016/j.clinthera.2009.07.011. Clin Ther. 2009. PMID: 19695403
-
Efficacy and safety of oral conivaptan, a vasopressin-receptor antagonist, evaluated in a randomized, controlled trial in patients with euvolemic or hypervolemic hyponatremia.Am J Med Sci. 2009 Jan;337(1):28-36. doi: 10.1097/MAJ.0b013e31817b8148. Am J Med Sci. 2009. PMID: 19057376 Clinical Trial.
-
Treatment of hypervolemic or euvolemic hyponatremia associated with heart failure, cirrhosis, or the syndrome of inappropriate antidiuretic hormone with tolvaptan: a clinical review.Clin Ther. 2010 Jun;32(6):1015-32. doi: 10.1016/j.clinthera.2010.06.015. Clin Ther. 2010. PMID: 20637957 Review.
-
Conivaptan: a dual vasopressin receptor v1a/v2 antagonist [corrected].Cardiovasc Drug Rev. 2007 Fall;25(3):261-79. doi: 10.1111/j.1527-3466.2007.00019.x. Cardiovasc Drug Rev. 2007. PMID: 17919259 Review.
Cited by
-
The role of v2 receptor antagonists in the treatment of hyponatremia.Electrolyte Blood Press. 2013 Jun;11(1):1-8. doi: 10.5049/EBP.2013.11.1.1. Epub 2013 Jun 30. Electrolyte Blood Press. 2013. PMID: 23946759 Free PMC article. No abstract available.
-
Vasopressin Receptor Antagonists in Hyponatremia: Uses and Misuses.Front Med (Lausanne). 2017 Aug 21;4:141. doi: 10.3389/fmed.2017.00141. eCollection 2017. Front Med (Lausanne). 2017. PMID: 28879182 Free PMC article. Review.
-
Hyponatremia in the intensive care unit: How to avoid a Zugzwang situation?Ann Intensive Care. 2015 Dec;5(1):39. doi: 10.1186/s13613-015-0066-8. Epub 2015 Nov 9. Ann Intensive Care. 2015. PMID: 26553121 Free PMC article.
-
Efficacy of conivaptan and hypertonic (3%) saline in treating hyponatremia due to syndrome of inappropriate antidiuretic hormone in a tertiary Intensive Care Unit.Indian J Crit Care Med. 2016 Dec;20(12):714-718. doi: 10.4103/0972-5229.195708. Indian J Crit Care Med. 2016. PMID: 28149029 Free PMC article.
-
Hyponatremia in cirrhosis and end-stage liver disease: treatment with the vasopressin V₂-receptor antagonist tolvaptan.Dig Dis Sci. 2012 Nov;57(11):2774-85. doi: 10.1007/s10620-012-2276-3. Epub 2012 Jun 26. Dig Dis Sci. 2012. PMID: 22732834 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical